Nektar Therapeutics (NKTR) News Headlines

▮ More

Date

Headline

8/16/2022 8:52:16 AM Nektar Therapeutics: Preclinical Findings Support Clinical Development Program For NKTR-255

8/16/2022 8:35:51 AM Nektar : Publication Of Preclinical Data For NKTR-255& Observed Improvement Of NK Cell Function In Multiple Myeloma

8/4/2022 4:34:49 PM Nektar Therapeutics Q2 Loss increases, but beats estimates

8/4/2022 4:21:50 PM Nektar Therapeutics Q2 Loss/share $0.85 Vs. Loss $0.69 Year Ago

8/4/2022 3:00:20 PM Nektar Therapeutics Q2 22 Earnings Conference Call At 5:00 PM ET

7/1/2022 6:45:32 AM Nektar Therapeutics Promotes Chief Accounting Officer Jillian Thomsen To CFO

7/1/2022 6:31:59 AM Nektar Promotes Jillian Thomsen To SVP And CFO

5/5/2022 4:51:43 PM Nektar Therapeutics Q1 Loss decreases, beats estimates

5/5/2022 4:17:23 PM Nektar Therapeutics Q1 Loss/share $0.49 Vs. Loss $0.68 Year Ago

4/18/2022 7:48:56 AM Pre-market Movers: TGTX, NKTR, MDVL, SGMA, INDO…

4/15/2022 3:15:54 AM Nektar, Bristol Myers To Discontinue Clinical Program For Bempegaldesleukin With Opdivo

4/14/2022 5:05:28 PM Nektar, Bristol Myers Announce Update On Clinical Development Program For Bempegaldesleukin In Combination With Opdivo

3/14/2022 7:38:57 AM Bristol Myers Squibb, Nektar Say Phase 3 PIVOT IO-001 Trial Fails To Meet Endpoints

2/28/2022 4:21:19 PM Nektar Therapeutics Q4 Loss/share $0.79 Vs. Loss $0.65 Year Ago

2/28/2022 4:18:10 PM Nektar Therapeutics Q4 Loss increases, but beats estimates

2/28/2022 3:00:19 PM Nektar Therapeutics Q4 21 Earnings Conference Call At 5:00 PM ET

12/15/2021 9:44:01 AM Nektar Announces Positive Phase 1b Data For NKTR-358 In Patients With Atopic Dermatitis

12/13/2021 9:05:23 AM Nektar Therapeutics Presents Data For NKTR-255 In Patients With Relapsed/Refractory Hematologic Malignancies

11/30/2021 8:05:29 AM Nektar Therapeutics Announces Data Presentations For Its Immuno-Oncology Programs

11/15/2021 8:32:53 AM Nektar Therapeutics Appoints Diana Brainard As Independent Director To Board